Company & Sponsor Intelligence

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials10

Recruiting0

Completed10

Countries1

Therapeutic footprint

adhdalzheimersautismepilepsy

Indexed studies

NCT00576732A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
autism · United StatesPHASE4

NCT00082602Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease
alzheimers · PHASE3

NCT00236860A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures
epilepsy · PHASE2

NCT00266604A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy
epilepsy · PHASE4

NCT00236743A Study of the Effectiveness and Safety of Topiramate in the Treatment of Children With Epilepsy
epilepsy · PHASE3

NCT00236444A Study of the Efficacy and Safety of Risperidone in the Prevention of Relapse in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders
adhd · PHASE3

NCT00236847A Study of the Efficacy and Safety of Topiramate in the Treatment of Patients With Epilepsy.
epilepsy · PHASE2

NCT00034762Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease
alzheimers · PHASE3

NCT01060228A Drug Interaction Study of Valproic Acid and Single-dose Paliperidone Extended-Release (ER) in Healthy Men
epilepsy · PHASE1

NCT00253214Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation
alzheimers · PHASE3

Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →